1672 Stock Overview
A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Ascletis Pharma Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$1.19 |
52 Week High | HK$2.26 |
52 Week Low | HK$0.78 |
Beta | 0.69 |
11 Month Change | 43.37% |
3 Month Change | -11.19% |
1 Year Change | -40.20% |
33 Year Change | -59.39% |
5 Year Change | -72.33% |
Change since IPO | -91.50% |
Recent News & Updates
Recent updates
We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate
Dec 19We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely
Aug 23What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today
Nov 03Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth
Oct 13Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates
Aug 24Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation
May 19Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts
Mar 27We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely
Feb 08Shareholder Returns
1672 | HK Biotechs | HK Market | |
---|---|---|---|
7D | 10.2% | -3.4% | -1.9% |
1Y | -40.2% | -38.2% | -6.7% |
Return vs Industry: 1672 underperformed the Hong Kong Biotechs industry which returned -38.2% over the past year.
Return vs Market: 1672 underperformed the Hong Kong Market which returned -6.7% over the past year.
Price Volatility
1672 volatility | |
---|---|
1672 Average Weekly Movement | 8.5% |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 6.7% |
10% most volatile stocks in HK Market | 14.1% |
10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 1672's share price has been volatile over the past 3 months.
Volatility Over Time: 1672's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 219 | Jinzi Jason Wu | www.ascletis.com |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.
Ascletis Pharma Inc. Fundamentals Summary
1672 fundamental statistics | |
---|---|
Market cap | HK$1.20b |
Earnings (TTM) | -HK$155.86m |
Revenue (TTM) | HK$60.95m |
19.7x
P/S Ratio-7.7x
P/E RatioIs 1672 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1672 income statement (TTM) | |
---|---|
Revenue | CN¥56.60m |
Cost of Revenue | CN¥30.61m |
Gross Profit | CN¥25.99m |
Other Expenses | CN¥170.71m |
Earnings | -CN¥144.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.14 |
Gross Margin | 45.92% |
Net Profit Margin | -255.70% |
Debt/Equity Ratio | 0% |
How did 1672 perform over the long term?
See historical performance and comparison